ArticleAdvances in rheumatology (London, England)2025
Correlation between body mass index and disease activity in patients with systemic lupus erythematosus from China.
Article in Advances in rheumatology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo assess the association between clinical indicators (primarily Body Mass Index, BMI) and disease activity in systemic lupus erythematosus (SLE) populations in a large population-based cohort.
methodsConsecutive patients with SLE were enrolled to investigate the relationships among clinical features, inflammatory and biochemical indicators, and disease activity parameters. Significance values were adjusted by Bonferroni correction for multiple tests, then differences between continuous variables were analyzed by Kruskal Wallis tests. Associations were assessed using multiple linear regression to adjust for potential confounders, including glucocorticoid use, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and lipid levels.
resultsA total of 400 SLE patients (375 women and 25 men) were included. Among them, 61 patients (15.25%) were classified into the low BMI group (BMI < 18.5 kg/m²), 267 patients (66.75%) into the normal BMI group (18.5 kg/m² ≤ BMI < 25 kg/m²), and 72 patients (18.00%) into the high BMI group (BMI ≥ 25 kg/m²). BMI was negatively correlated with SLE disease activity index (SLEDAI) score (ρ = -0.11, P = 0.02). This inverse association remained significant in multivariate linear regression after adjusting for potential confounders, including glucocorticoid use, CRP, ESR, and lipid levels. Patients in the low BMI group exhibited higher mean SLEDAI scores and a greater proportion of moderate to severe disease activity (SLEDAI ≥ 10) compared with the normal and high BMI groups. Additionally, anti-dsDNA, complement component 3, white blood cell count, alanine aminotransferase, neutrophil count, and hemoglobin were significantly different between the low BMI group and the other two groups.
conclusionsThese findings indicate an association between low BMI and higher SLE disease activity. However, further investigation, particularly through prospective studies, is needed to determine whether low BMI exerts a detrimental effect on disease activity. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.